Identifying brain and inflammation markers in older adults at risk of dementia
Identification of Neuroinflammation and Neuroimaging Biomarkers Through Data Driven Artificial Intelligence Techniques for Unraveling the Heterogeneity of Aged Subjects at Risk of Dementia and to Better Inform Prevention Strategies
This study is trying to find specific brain and inflammation signs in older adults with early memory problems to help identify those at risk for dementia and create better early treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 115 (estimated) |
| Ages | 65 Years to 89 Years |
| Sex | All |
| Sponsor | IRCCS Fondazione Stella Maris Academic / other |
| Locations | 1 site (Pisa) |
| Trial ID | NCT06746909 on ClinicalTrials.gov |
What this trial studies
This study aims to identify neuroinflammation and neuroimaging biomarkers in older adults with Mild Cognitive Impairment (MCI) and Subjective Cognitive Decline (SCD) using data-driven artificial intelligence techniques. By analyzing brain structure, cerebral blood flow, and immune cell populations, the study seeks to characterize subgroups at high risk for dementia. Participants will undergo cognitive assessments and MR imaging at various intervals, and blood samples will be collected to evaluate inflammatory markers. The ultimate goal is to develop tailored early interventions for those showing cognitive decline.
Who should consider this trial
Good fit: Ideal candidates are older adults aged 65 to 89 with a diagnosis of Mild Cognitive Impairment or Subjective Cognitive Decline.
Not a fit: Patients with neurological disorders, dementia, or psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized prevention strategies for individuals at risk of developing dementia.
How similar studies have performed: Other studies have shown promise in using neuroimaging and inflammatory markers to predict dementia risk, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age between 65 and 89 years; 5 years of schooling; * diagnosis of Mild Cognitive Impairment (Croisile et al., 2011) or * diagnosis of Subjective Cognitive Decline (Jessen et al., 2014). Exclusion Criteria: * neurological pathologies; dementia; * psychiatric disorders; * pathologies or orthopedic problems limiting participation to the aerobic physical training program and to the MR imaging.
Where this trial is running
Pisa
- Azienda Ospedaliera Universitaria Pisana — Pisa, Italy (Recruiting)
Study contacts
- Study coordinator: Paolo Bosco Bosco, PhD
- Email: paolo.bosco@fsm.unipi.it
- Phone: +39 050886180
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.